Core Viewpoint - Company maintains strong resilience in its industrial purification business, driven by "domestic substitution + natural project advancement" amid fluctuations in the pharmaceutical industry's investment and financing [2][4]. Group 1: Business Development and Industry Dynamics - Company engages in discussions with investors regarding industry conditions and product market dynamics, confirming alignment with company announcements [2]. - The growth of the company's industrial purification business is significantly correlated with the investment and financing situation in the pharmaceutical industry [2]. Group 2: Competitive Advantages and Barriers to Entry - Industry barriers are primarily based on long-term technological accumulation, large-scale production, quality control, and customer stickiness [3]. - Company's competitive advantages include: 1. Extensive technical accumulation in chromatography materials, with over 20 years of experience and proprietary technologies [3]. 2. Capability for large-scale production and a high-level quality management system, supported by audits from over 100 pharmaceutical clients [3]. 3. Strong customer relationships with over 5,000 global clients, including long-term partnerships with major companies like Gilent, Merck, and Thermo Fisher [3]. Group 3: Future Planning and Capacity Utilization - Company plans to leverage the strategic window for domestic substitution over the next five years while expanding its global footprint to meet unmet market demands [4]. - Current capacity utilization is high, with plans to optimize production processes to meet order demands. The completion of the second phase of the Yangzhou project will enable an annual production capacity of over 200,000 liters of biopharmaceutical chromatography media [5]. Group 4: Financial Performance - In Q1 2025, the company reported a main revenue of 83.59 million yuan, an increase of 8.87% year-on-year, while net profit attributable to shareholders was 23.71 million yuan, a decrease of 1.02% year-on-year [5]. - The company has a debt ratio of 5.2% and a gross profit margin of 74.14% [5]. Group 5: Market Sentiment and Analyst Ratings - In the last 90 days, two institutions have given a rating of "buy" for the stock, with a target average price of 17.85 yuan [6]. - Recent financing data indicates a net inflow of 27.51 million yuan in the last three months, suggesting positive market sentiment [8].

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 2.07%, closing at 1054.20 points, with a total trading volume of 4.485 billion shares and a turnover of 151.892 billion yuan, resulting in an average turnover rate of 2.47% [1] - Among the tradable stocks on the STAR Market, 401 stocks closed higher, with 11 stocks increasing by over 10% and 40 stocks rising between 5% and 10%. Conversely, 185 stocks closed lower, with 1 stock declining by over 10% [1] Turnover Rate Analysis - The distribution of turnover rates shows that 22 stocks had a turnover rate between 10% and 20%, 91 stocks between 5% and 10%, 119 stocks between 3% and 5%, 289 stocks between 1% and 3%, and 68 stocks had a turnover rate of less than 1% [1] - The stock with the highest turnover rate was Xinyuren, which closed down by 5.16% with a turnover rate of 19.52% and a transaction amount of 317 million yuan. Other notable stocks included Saifen Technology and Qingyun Technology, with turnover rates of 16.87% and 15.62%, respectively [1] Sector Performance - In terms of industry, the pharmaceutical and biotechnology sector had the highest number of stocks with a turnover rate exceeding 5%, totaling 32 stocks, followed by the electronics and computer sectors with 27 and 20 stocks, respectively [2] - Among high turnover stocks, 62 experienced net inflows of main funds, with the highest net inflows recorded for Yuncong Technology, Youkede, and Gaomei Shares, amounting to 118 million yuan, 88.645 million yuan, and 73.8116 million yuan, respectively [2] Leverage Fund Movements - A total of 78 high turnover stocks received net purchases from leveraged funds, with notable increases in financing balances for Tiejian Heavy Industry, Shangwei New Materials, and Shijia Photon, which saw increases of 356 million yuan, 277 million yuan, and 218 million yuan, respectively [2] - Conversely, stocks such as Jinchengzi, Fuliwang, and Zhongke Lanyun experienced significant decreases in financing balances, with reductions of 30.322 million yuan, 27.8513 million yuan, and 25.3532 million yuan, respectively [2] Earnings Reports - Among high turnover stocks, one company reported a net profit increase of 2147.93%, while another company announced a half-year performance report with a net profit increase of 50.89% [2]

Summary of the Conference Call for Sifen Technology Company Overview - Sifen Technology reported an industrial chromatography filler revenue of 187 million yuan in 2024, with 85% of this revenue coming from registered clinical stages and commercialization projects, primarily from antibody drugs, insulin, peptides, GLP-1 drugs, and recombinant proteins [2][8] - The company’s chromatography column business generated 124 million yuan in revenue in 2024, with approximately 70 million yuan coming from the U.S. market [2][8] - The domestic chromatography filler market is estimated to be around 6-7 billion yuan, with domestic products holding less than 20% market share, indicating significant potential for domestic substitution [2][11] Market Dynamics - The global chromatography column production is approximately 4.5 million units, with an expected production of 229,000 units in China by 2025. Sifen's sales volume is currently low, but there is substantial growth potential [2][13] - The company’s industrial purification segment has shown significant revenue growth, exceeding 100% in both 2020 and 2021. In 2024, the revenue from the third phase and commercialization reached 168 million yuan, accounting for 85% of total chromatography filler revenue [2][12] Future Projections - Revenue growth rates for chromatography media are projected at 30%, 28%, and 26% for 2025 to 2027, while the overall growth rates for chromatography columns are expected to be 10%, 9%, and 8.4% respectively [3][16] - The company plans to expand its production capacity significantly, with the second phase of the Yangzhou facility expected to add 200,000 liters of capacity, increasing total capacity to ten times that of the first phase [2][15] Competitive Landscape - The domestic chromatography filler market has a low domesticization rate, with significant room for growth. The overseas market is estimated to be five times larger than the domestic market, around 30 billion yuan [2][11] - The company collaborates with major clients in the antibody and insulin sectors, including Innovent Biologics, Fuhong Hanlin, and Gland Pharma, indicating a strong position in the market [2][14] Investment Recommendation - The company is positioned well for future growth due to the potential for domestic substitution and stable or slightly increasing gross margins. An optimistic outlook is maintained for Sifen Technology, with a recommendation for investment [2][16]

Core Viewpoint - The company, Saifen Technology, is expected to achieve significant revenue and profit growth in the first half of 2025, driven by its focus on analytical chromatography and industrial purification sectors, alongside strong market demand and strategic partnerships [1][2]. Company Performance - The company forecasts revenue between 180 million to 186 million yuan, representing a year-on-year growth of 18% to 22% [1]. - Expected net profit attributable to shareholders is projected to be between 51 million to 55 million yuan, indicating a year-on-year increase of 34% to 44% [1]. - The net profit after deducting non-recurring gains and losses is anticipated to be between 45 million to 47 million yuan, reflecting a year-on-year growth of 18% to 23% [1]. Market Position and Strategy - Saifen Technology holds three core technologies: microspheres, surface modification, and functional group ligands, and has established strategic partnerships with leading companies in the antibody, insulin, GLP-1, and recombinant protein sectors [1]. - The company is actively developing purification solutions for oligonucleotides, collagen, and blood products, enhancing its competitive edge across various segments of the biopharmaceutical market [1]. Industry Trends - The Chinese biopharmaceutical chromatography medium market is projected to reach between 6 billion to 9 billion yuan, accounting for approximately 15% to 20% of the global market [2]. - There is a strong trend towards domestic substitution in the industry, with leading domestic companies gaining market advantages through technological depth, scale production capabilities, and quality systems [2]. - The company is expanding its core product capacity and shortening delivery times to meet the rapidly growing market demand, with a significant capacity expansion project underway at its Yangzhou factory [2].

[Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company forecasts H1 2025 revenue of RMB 180-186 million, with net profit attributable to shareholders of RMB 51-55 million 2025 Semi-Annual Performance Forecast | Indicator | Estimated Amount (Million RMB) | YoY Growth Rate | | :--- | :--- | :--- | | Operating Revenue | 180.00 - 186.00 | 18% - 22% | | Net Profit Attributable to Shareholders | 51.00 - 55.00 | 34% - 44% | | Net Profit Excluding Non-Recurring Items | 45.00 - 47.00 | 18% - 23% | - This performance forecast has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance](index=1&type=section&id=Item%202.%20Prior%20Period%20Performance) H1 2024 results, including RMB 152 million revenue and RMB 38.08 million net profit, serve as the comparative basis for the current forecast 2024 Semi-Annual Performance Review | Indicator | Amount | | :--- | :--- | | Operating Revenue | RMB 152.4927 million | | Net Profit Attributable to Shareholders | RMB 38.0793 million | | Net Profit Excluding Non-Recurring Items | RMB 38.0924 million | | Earnings Per Share | RMB 0.10 | [Analysis of Performance Changes](index=2&type=section&id=Item%203.%20Main%20Reasons%20for%20Performance%20Changes) Performance growth is driven by strategic focus on core areas, market expansion, and leveraging R&D to acquire new clients and boost repeat purchases - The company's strategy focuses on two core areas: analytical chromatography and industrial purification, with continuous market expansion[8](index=8&type=chunk) - Leveraging product performance and independent R&D advantages, the company continuously develops new client projects and actively promotes repeat purchases from existing clients, achieving expanded business scale and stable profitability enhancement[8](index=8&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=Item%204.%20Risk%20Warning) The company confirms no major uncertainties affecting the forecast but reminds investors that the preliminary data is unaudited - The company states that as of the announcement date, there are no significant uncertainties affecting the accuracy of this performance forecast[9](index=9&type=chunk) - The company reminds that the forecast data is preliminary and unaudited, and specific financial data will be subject to the officially disclosed 2025 semi-annual report; investors are advised to be aware of investment risks[9](index=9&type=chunk)[10](index=10&type=chunk)

赛分科技公告，预计2025年半年度实现营业收入1.8亿元到1.86亿元，与上年同期相比，将增加人民币 2750.73万元到3350.73万元，同比增长18%到22%。预计实现归属于母公司所有者的净利润5100万元到 5500万元，与上年同期相比，将增加人民币1292.07万元到1692.07万元，同比增长34%到44%。预计实 现归属于母公司所有者扣除非经常性损益后的净利润4500万元到4700万元，与上年同期相比，将增加人 民币690.76万元到890.76万元，同比增长18%到23%。 ...

Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Suzhou Saifen Technology Co., Ltd., which will occur on July 10, 2025, following the expiration of a six-month lock-up period for shares allocated through offline placement [1][2]. Group 1: Listing Details - The total number of shares to be listed is 2,975,050, representing 0.71% of the company's total share capital [4]. - The shares are part of the company's initial public offering (IPO) and are subject to a six-month lock-up period that began on January 10, 2025 [2][3]. - The company received approval from the China Securities Regulatory Commission for its IPO, allowing it to issue a total of 49,975,690 shares, with a total share capital of 416,464,084 shares post-IPO [1][2]. Group 2: Shareholder Commitments - Shareholders of the restricted shares have committed to a lock-up period of six months, with 10% of their allocated shares subject to this restriction [2][3]. - As of the announcement date, all shareholders have adhered to their commitments, ensuring no issues that would affect the upcoming circulation of restricted shares [2][3]. Group 3: Underwriter's Verification - The underwriter, CITIC Securities Co., Ltd., has confirmed that all shareholders have complied with their lock-up commitments, and the details regarding the circulation of restricted shares meet regulatory requirements [3].

证券代码：688758 证券简称：赛分科技 公告编号：2025-026 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 2,975,050股。 本次股票上市流通总数为2,975,050股。 本次股票上市流通日期为2025 年 7 月 10 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 8 月 22 日出具的《关于同意苏州赛分科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2024〕1204 号），公司获准首次向社会公众公开发行人民币普通股（A 股）股票 4,997.5690 万股，并于 2025 年 1 月 10 日在上海证券交易所科创板上市。 公司首次公开发行股票完成后，总股本为 416,464,084 股，其中有限售条件流通 股 376,959,798 股，占公司总股本的 90.51%，无限售条件流通股 39,504,286 股， 占公司总股本的 9.49%。 本次上市流通的限售股为公司首次公开发行网下配售限售股，股份数量为 2,975,050 股，占公司总股本的比例为 0.71%。上述股份锁定期为自公司 ...

中信证券股份有限公司 关于苏州赛分科技股份有限公司 首次公开发行网下配售限售股份上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为苏州赛 分科技股份有限公司（以下简称"赛分科技"、"公司"）首次公开发行股票并 在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》 等有关法律法规和规范性文件的要求，就赛分科技 首次公开发行网下配售限售股份上市流通的事项进行了专项核查： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2024 年 8 月 22 日出具的《关于同意苏州赛分科技股份有限公司首次公开发行股票注册的批 复》（证监许可〔2024〕1204 号），公司获准首次向社会公众公开发行人民币 普通股（A 股）股票 4,997.5690 万股，并于 2025 年 1 月 10 日在上海证券交易所 科创板上市。公司首次公开发行股票完成后，总股本为 416,464,084 股，其中有 限售条件流通股 376,959,798 股，占公司总股本的 90.51%，无限售条件流通股 39,504,286 股，占公司总股 ...

Core Insights - A total of 51 new companies were listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange from January to June 2025, raising a total of 37.3 billion yuan [1] - Among these, 7 companies were listed on the Sci-Tech Innovation Board, collectively raising 5.619 billion yuan [1] Listing Details - The 7 companies that chose the first set of listing standards include: - Ying Shi Innovation (688775.SH) listed on June 11, 2025, raising 1.93807 billion yuan with underwriting fees of 158.3475 million yuan [1] - Han Bang Technology (688755.SH) listed on May 16, 2025, raising 500.94 million yuan with underwriting fees of 37.2891 million yuan [1] - Sheng Ke Nano (688757.SH) listed on March 25, 2025, raising 366.21 million yuan with underwriting fees of 43.9448 million yuan [1] - Hai Bo Si Chuang (688411.SH) listed on January 27, 2025, raising 861.1 million yuan with underwriting fees of 66.4722 million yuan [1] - Xing Fu Electronics (688545.SH) listed on January 22, 2025, raising 1.168 billion yuan with underwriting fees of 82.0755 million yuan [1] - Si Kan Technology (688583.SH) listed on January 15, 2025, raising 568.82 million yuan with underwriting fees of 46.0744 million yuan [1] - Sai Fen Technology (688758.SH) listed on January 10, 2025, raising 215.89 million yuan with underwriting fees of 25.283 million yuan [1] Listing Standards - The listing standards for the Sci-Tech Innovation Board require either: - An expected market value of no less than 1 billion yuan, positive net profits for the last two years, and a cumulative net profit of no less than 50 million yuan, or - An expected market value of no less than 1 billion yuan, positive net profit for the last year, and operating revenue of no less than 100 million yuan [1]